Some cancer patients, breast cancer survivors in particular, have reported a link between permanent hair loss and the chemotherapy drug Taxotere® (Docetaxel). While temporary hair loss from chemotherapy is common, worrying about permanent hair loss should not have to be a concern.

Anvil Legal Group is reviewing cases involving women who took the chemotherapy drug Taxotere® and have suffered from permanent hair loss or permanent significant alopecia following six months or more of a significant lack of hair regrowth.

Learn More


What to know about Taxotere lawsuits

Taxotere Side Effects

Taxotere is given through injection and is associated with side effects that are common for chemotherapy drugs, including:

  • mouth sores
  • nausea
  • excessive fatigue
  • muscle or bone pain
  • low platelet count

An increasing number of women have reported permanent hair loss to the FDA as a result of being treated with Taxotere, claiming that they were not warned of a potential side effect of permanent hair loss. The warning of permanent significant alopecia (hair loss) was not added to the Taxotere label by the FDA until December 2015.

Background of Taxotere

Taxotere is an anti-cancer chemotherapy drug that also goes by the generic name Docetaxel. Taxotere is classified as a plant alkaloid and was approved in 2006 by the FDA for treatment of:

  • breast cancer
  • non-small cell lung cancer
  • advanced stomach cancer
  • head and neck cancer
  • metastatic prostate cancer
  • small cell lung cancer
  • ovarian cancer
  • bladder cancer
  • pancreatic cancer
  • soft tissue sarcoma
  • melanoma

In 2010, Sanofi-Aventis removed language from its label that “hair generally grows back,” and in 2015, Sanofi-Aventis added in the Adverse Reactions section of the Taxotere label that “cases of permanent hair loss have been reported.”

Get a free consultation

Let's talk about your case. Call us or fill out the form for a free evaluation.